Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023557896> ?p ?o ?g. }
- W2023557896 endingPage "970.e11" @default.
- W2023557896 startingPage "961" @default.
- W2023557896 abstract "Background OnabotulinumtoxinA for the treatment of facial lines is a widely used cosmetic medical procedure and, as such, the safety and tolerability profile is of interest to health care providers and patients. Based on data from individual studies that were conducted according to regulatory guidelines to provide adequate safety and efficacy data to support product licensure (registration studies), the overall benefit:risk profile of onabotulinumtoxinA for facial lines has been favorable. Objective Our objective was to increase statistical power through meta-analysis to detect treatment group differences in adverse event (AE) incidence that may not have been evident in individual registration studies. Methods Individual participant data (n = 1678) were from 6 randomized, double-blind, placebo-controlled and 3 open-label studies. Two double-blind, placebo-controlled studies were for lateral canthal lines (3-18 U/side) and all others were for glabellar lines (10 or 20 U). Doses used reflect global product labeling in countries where licensed. Results Participant population was non-Hispanic white (43%) or Asian (52%) and predominantly female (88%). In double-blind, placebo-controlled studies, overall AE incidence did not significantly differ by treatment group (onabotulinumtoxinA vs placebo). The only individual AEs with significantly greater incidence in the onabotulinumtoxinA group were eyelid sensory disorder (2.5% vs 0.3%, P = .004; verbatim phrases “tight,” “pressured,” “heavy,” “drooping feeling,” “feeling of droopiness”) and eyelid ptosis (1.8% vs 0%, P = .02), both present only in glabellar studies. Overall treatment-related (per investigator) AE incidence was greater in the onabotulinumtoxinA group versus placebo (24% vs 16%, P = .005), and treatment-related eyelid edema was an additional AE with significantly higher incidence in the onabotulinumtoxinA group versus placebo (P = .04). Incidence of all 3 of these AEs significantly decreased as number of treatment cycles increased. Eyelid sensory disorder and eyelid edema were more common in Asian participants. Acne, injection site pruritus, oral herpes, rash, lower respiratory tract infection, dental caries, and eye pain were significantly more common in placebo-treated compared with onabotulinumtoxinA-treated participants. Serious AE incidence did not significantly differ by treatment (onabotulinumtoxinA vs placebo) and no serious AEs were treatment related. There were no symptoms of weakness remote to the injection site or related to the central nervous system. Limitations Limitations included: (1) highly visible efficacy of onabotulinumtoxinA may have resulted in reporting bias; (2) reliance on participant intervisit recall; (3) a relatively short follow-up period (1 year); (4) conclusions are based solely on the doses analyzed (ie, those used in the respective trials); and (5) exclusion of patients with severe medical disease in registration studies. Conclusion This meta-analysis confirms the safety and tolerability of onabotulinumtoxinA for glabellar and lateral canthal lines, at the doses studied, based on the most comprehensive controlled safety analysis of onabotulinumtoxinA performed to date. The AEs observed were generally mild to moderate; most treatment-related AEs were related either to physical injection of product or local pharmacologic effects. Even with the increased statistical power of a large sample size, no new onabotulinumtoxinA-associated AEs emerged. OnabotulinumtoxinA for the treatment of facial lines is a widely used cosmetic medical procedure and, as such, the safety and tolerability profile is of interest to health care providers and patients. Based on data from individual studies that were conducted according to regulatory guidelines to provide adequate safety and efficacy data to support product licensure (registration studies), the overall benefit:risk profile of onabotulinumtoxinA for facial lines has been favorable. Our objective was to increase statistical power through meta-analysis to detect treatment group differences in adverse event (AE) incidence that may not have been evident in individual registration studies. Individual participant data (n = 1678) were from 6 randomized, double-blind, placebo-controlled and 3 open-label studies. Two double-blind, placebo-controlled studies were for lateral canthal lines (3-18 U/side) and all others were for glabellar lines (10 or 20 U). Doses used reflect global product labeling in countries where licensed. Participant population was non-Hispanic white (43%) or Asian (52%) and predominantly female (88%). In double-blind, placebo-controlled studies, overall AE incidence did not significantly differ by treatment group (onabotulinumtoxinA vs placebo). The only individual AEs with significantly greater incidence in the onabotulinumtoxinA group were eyelid sensory disorder (2.5% vs 0.3%, P = .004; verbatim phrases “tight,” “pressured,” “heavy,” “drooping feeling,” “feeling of droopiness”) and eyelid ptosis (1.8% vs 0%, P = .02), both present only in glabellar studies. Overall treatment-related (per investigator) AE incidence was greater in the onabotulinumtoxinA group versus placebo (24% vs 16%, P = .005), and treatment-related eyelid edema was an additional AE with significantly higher incidence in the onabotulinumtoxinA group versus placebo (P = .04). Incidence of all 3 of these AEs significantly decreased as number of treatment cycles increased. Eyelid sensory disorder and eyelid edema were more common in Asian participants. Acne, injection site pruritus, oral herpes, rash, lower respiratory tract infection, dental caries, and eye pain were significantly more common in placebo-treated compared with onabotulinumtoxinA-treated participants. Serious AE incidence did not significantly differ by treatment (onabotulinumtoxinA vs placebo) and no serious AEs were treatment related. There were no symptoms of weakness remote to the injection site or related to the central nervous system. Limitations included: (1) highly visible efficacy of onabotulinumtoxinA may have resulted in reporting bias; (2) reliance on participant intervisit recall; (3) a relatively short follow-up period (1 year); (4) conclusions are based solely on the doses analyzed (ie, those used in the respective trials); and (5) exclusion of patients with severe medical disease in registration studies. This meta-analysis confirms the safety and tolerability of onabotulinumtoxinA for glabellar and lateral canthal lines, at the doses studied, based on the most comprehensive controlled safety analysis of onabotulinumtoxinA performed to date. The AEs observed were generally mild to moderate; most treatment-related AEs were related either to physical injection of product or local pharmacologic effects. Even with the increased statistical power of a large sample size, no new onabotulinumtoxinA-associated AEs emerged." @default.
- W2023557896 created "2016-06-24" @default.
- W2023557896 creator A5000630505 @default.
- W2023557896 creator A5011976174 @default.
- W2023557896 creator A5023253215 @default.
- W2023557896 creator A5032430292 @default.
- W2023557896 creator A5049158075 @default.
- W2023557896 creator A5055446159 @default.
- W2023557896 creator A5065651957 @default.
- W2023557896 creator A5070581964 @default.
- W2023557896 creator A5088972033 @default.
- W2023557896 date "2009-12-01" @default.
- W2023557896 modified "2023-10-16" @default.
- W2023557896 title "Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participants" @default.
- W2023557896 cites W168854692 @default.
- W2023557896 cites W1966004611 @default.
- W2023557896 cites W1966953116 @default.
- W2023557896 cites W1967166816 @default.
- W2023557896 cites W1973788946 @default.
- W2023557896 cites W1978910356 @default.
- W2023557896 cites W1980918252 @default.
- W2023557896 cites W1985296111 @default.
- W2023557896 cites W2004412029 @default.
- W2023557896 cites W2017012921 @default.
- W2023557896 cites W2022807726 @default.
- W2023557896 cites W2028843172 @default.
- W2023557896 cites W2030466283 @default.
- W2023557896 cites W2039811433 @default.
- W2023557896 cites W2043661731 @default.
- W2023557896 cites W2047796878 @default.
- W2023557896 cites W2071022748 @default.
- W2023557896 cites W2079176475 @default.
- W2023557896 cites W2095244037 @default.
- W2023557896 cites W2110018721 @default.
- W2023557896 cites W2122136483 @default.
- W2023557896 cites W2126930838 @default.
- W2023557896 cites W2142038792 @default.
- W2023557896 cites W2157011198 @default.
- W2023557896 cites W2170952317 @default.
- W2023557896 cites W2171838635 @default.
- W2023557896 cites W2189421285 @default.
- W2023557896 cites W2315123323 @default.
- W2023557896 cites W4252071217 @default.
- W2023557896 cites W4255561326 @default.
- W2023557896 doi "https://doi.org/10.1016/j.jaad.2009.06.040" @default.
- W2023557896 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19744746" @default.
- W2023557896 hasPublicationYear "2009" @default.
- W2023557896 type Work @default.
- W2023557896 sameAs 2023557896 @default.
- W2023557896 citedByCount "105" @default.
- W2023557896 countsByYear W20235578962012 @default.
- W2023557896 countsByYear W20235578962013 @default.
- W2023557896 countsByYear W20235578962014 @default.
- W2023557896 countsByYear W20235578962015 @default.
- W2023557896 countsByYear W20235578962016 @default.
- W2023557896 countsByYear W20235578962017 @default.
- W2023557896 countsByYear W20235578962018 @default.
- W2023557896 countsByYear W20235578962019 @default.
- W2023557896 countsByYear W20235578962020 @default.
- W2023557896 countsByYear W20235578962021 @default.
- W2023557896 countsByYear W20235578962022 @default.
- W2023557896 countsByYear W20235578962023 @default.
- W2023557896 crossrefType "journal-article" @default.
- W2023557896 hasAuthorship W2023557896A5000630505 @default.
- W2023557896 hasAuthorship W2023557896A5011976174 @default.
- W2023557896 hasAuthorship W2023557896A5023253215 @default.
- W2023557896 hasAuthorship W2023557896A5032430292 @default.
- W2023557896 hasAuthorship W2023557896A5049158075 @default.
- W2023557896 hasAuthorship W2023557896A5055446159 @default.
- W2023557896 hasAuthorship W2023557896A5065651957 @default.
- W2023557896 hasAuthorship W2023557896A5070581964 @default.
- W2023557896 hasAuthorship W2023557896A5088972033 @default.
- W2023557896 hasConcept C120665830 @default.
- W2023557896 hasConcept C121332964 @default.
- W2023557896 hasConcept C126322002 @default.
- W2023557896 hasConcept C141071460 @default.
- W2023557896 hasConcept C142724271 @default.
- W2023557896 hasConcept C168563851 @default.
- W2023557896 hasConcept C197934379 @default.
- W2023557896 hasConcept C204787440 @default.
- W2023557896 hasConcept C27081682 @default.
- W2023557896 hasConcept C2778375690 @default.
- W2023557896 hasConcept C2908647359 @default.
- W2023557896 hasConcept C61511704 @default.
- W2023557896 hasConcept C71924100 @default.
- W2023557896 hasConcept C99454951 @default.
- W2023557896 hasConceptScore W2023557896C120665830 @default.
- W2023557896 hasConceptScore W2023557896C121332964 @default.
- W2023557896 hasConceptScore W2023557896C126322002 @default.
- W2023557896 hasConceptScore W2023557896C141071460 @default.
- W2023557896 hasConceptScore W2023557896C142724271 @default.
- W2023557896 hasConceptScore W2023557896C168563851 @default.
- W2023557896 hasConceptScore W2023557896C197934379 @default.
- W2023557896 hasConceptScore W2023557896C204787440 @default.
- W2023557896 hasConceptScore W2023557896C27081682 @default.
- W2023557896 hasConceptScore W2023557896C2778375690 @default.
- W2023557896 hasConceptScore W2023557896C2908647359 @default.
- W2023557896 hasConceptScore W2023557896C61511704 @default.